These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 33724511)

  • 1. Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease.
    Alexopoulos AS; Crowley MJ; Wang Y; Moylan CA; Guy CD; Henao R; Piercy DL; Seymour KA; Sudan R; Portenier DD; Diehl AM; Coviello AD; Abdelmalek MF
    Hepatology; 2021 Sep; 74(3):1220-1233. PubMed ID: 33724511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycemic Control Is Associated with Histological Findings of Nonalcoholic Fatty Liver Disease.
    Miyake T; Furukawa S; Matsuura B; Yoshida O; Miyazaki M; Shiomi A; Kanamoto A; Nakaguchi H; Nakamura Y; Imai Y; Koizumi M; Watanabe T; Yamamoto Y; Koizumi Y; Tokumoto Y; Hirooka M; Kumagi T; Takesita E; Ikeda Y; Abe M; Hiasa Y
    Diabetes Metab J; 2024 May; 48(3):440-448. PubMed ID: 38310878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
    Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
    J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease.
    Kakisaka K; Suzuki Y; Fujiwara Y; Abe T; Yonezawa M; Kuroda H; Ishida K; Sugai T; Takikawa Y
    J Gastroenterol; 2018 Dec; 53(12):1285-1291. PubMed ID: 29680867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 6. Acidophil bodies in nonalcoholic steatohepatitis.
    Yeh MM; Belt P; Brunt EM; Kowdley KV; Wilson LA; Ferrell L;
    Hum Pathol; 2016 Jun; 52():28-37. PubMed ID: 26980020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance, but not insulin response, during oral glucose tolerance test (OGTT) is associated to worse histological outcome in obese NAFLD.
    Coccia F; Testa M; Guarisco G; Di Cristofano C; Silecchia G; Leonetti F; Gastaldelli A; Capoccia D
    Nutr Metab Cardiovasc Dis; 2020 Jan; 30(1):106-113. PubMed ID: 31677889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trajectories of Liver Fibrosis and Gene Expression Profiles in Nonalcoholic Fatty Liver Disease Associated With Diabetes.
    Sako S; Takeshita Y; Takayama H; Goto H; Nakano Y; Ando H; Tsujiguchi H; Yamashita T; Arai K; Kaneko S; Nakamura H; Harada K; Honda M; Takamura T
    Diabetes; 2023 Sep; 72(9):1297-1306. PubMed ID: 37343270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.
    Lai LL; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    Dig Dis Sci; 2020 Feb; 65(2):623-631. PubMed ID: 30684076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
    McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis.
    Chatterjee A; Basu A; Das K; Singh P; Mondal D; Bhattacharya B; Roychoudhury S; Majumder PP; Chowdhury A; Basu P
    Ann Hepatol; 2020; 19(5):472-481. PubMed ID: 32682086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH).
    Giashuddin S; Alawad M
    Methods Mol Biol; 2022; 2455():1-18. PubMed ID: 35212981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease.
    Hashiba M; Ono M; Hyogo H; Ikeda Y; Masuda K; Yoshioka R; Ishikawa Y; Nagata Y; Munekage K; Ochi T; Hirose A; Nozaki-Fujimura Y; Noguchi S; Okamoto N; Chayama K; Suganuma N; Saibara T
    PLoS One; 2013; 8(11):e76161. PubMed ID: 24223115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.
    Brunt EM; Clouston AD; Goodman Z; Guy C; Kleiner DE; Lackner C; Tiniakos DG; Wee A; Yeh M; Leow WQ; Chng E; Ren Y; Boon Bee GG; Powell EE; Rinella M; Sanyal AJ; Neuschwander-Tetri B; Younossi Z; Charlton M; Ratziu V; Harrison SA; Tai D; Anstee QM
    J Hepatol; 2022 May; 76(5):1030-1041. PubMed ID: 35090960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
    Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
    JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of glycated hemoglobin with the risk of advanced fibrosis in non-alcoholic fatty liver disease patients without diabetes.
    Yu C; Wang L; Xue H; Lin H; Li Y; Chan SO
    Clin Res Hepatol Gastroenterol; 2019 Feb; 43(1):58-66. PubMed ID: 30274911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term luseogliflozin therapy improves histological activity of non-alcoholic steatohepatitis accompanied by type 2 diabetes mellitus.
    Fujimori N; Tanaka N; Kimura T; Sano K; Horiuchi A; Kato N; Takahashi Y; Kuribayashi N; Sugiura A; Yamazaki T; Joshita S; Umemura T; Matsumoto A; Tanaka E
    Clin J Gastroenterol; 2020 Feb; 13(1):83-89. PubMed ID: 31292843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis.
    Kamada Y; Akita M; Takeda Y; Yamada S; Fujii H; Sawai Y; Doi Y; Asazawa H; Nakayama K; Mizutani K; Fujii H; Yakushijin T; Miyazaki M; Ezaki H; Hiramatsu N; Yoshida Y; Kiso S; Imai Y; Kawada N; Takehara T; Miyoshi E
    PLoS One; 2013; 8(6):e66328. PubMed ID: 23805214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.